New small molecules for the treatment of Parkinson's disease (Q33636631)

28 July 2017

1 reference

title

New small molecules for the treatment of Parkinson's disease (English)

1 reference

28 July 2017

1 reference

1

Thomas Müller

1 reference

PubMed ID

20645881

28 July 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

Expert Opinion on Investigational Drugs

28 July 2017

1 reference

28 July 2017

19

1 reference

28 July 2017

9

1 reference

28 July 2017

1077-1086

1 reference

Levodopa, motor fluctuations and dyskinesia in Parkinson's disease

28 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Dopaminergic substitution in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Current pharmacotherapeutic treatment options in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Examining Braak's hypothesis by imaging Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Unilateral pedunculopontine stimulation improves falls in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Diagnostic staging of Parkinson's disease: conceptual aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Monoamine oxidase-B inhibition in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

There is no Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Distinction between benign and malignant type of parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Placebo influences on dyskinesia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Improvement of motor function in early Parkinson disease by safinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

What do clinical trials tell us about treating patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Gene therapy in Parkinson's disease: rationale and current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Gene therapy in hemiparkinsonian rhesus monkeys: long-term survival and behavioral recovery by transplantation of autologous human tyrosine hydroxylase-expressing neural stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Spheramine for treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Pathologic findings in retinal pigment epithelial cell implantation for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Role of homocysteine in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

The effect of deprenyl and levodopa on the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504711

10.1517/13543784.2010.504711

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

20645881